|  | RMST at times (years) | | | | | Survival proportions at times (years) | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment | Source | 4 | 8 | 15 | | 4 | | 8 | | 15 | |
| FC | Observed | 3.56 | 5.99 |  | | 0.77 | | 0.41 | |  | |
|  | Semi-Markov: SPM (Williams 2017) | 3.50 | 5.47 | 6.46 | | 0.70 | | 0.30 | | 0.05 | |
|  | Semi-Markov: FPM | 3.63 | 6.05 | 8.12 | | 0.77 | | 0.46 | | 0.18 | |
|  | Microsimulation: SPM, ASF (+now()) | 3.52 | 5.59 | 6.80 | | 0.72 | | 0.33 | | 0.08 | |
|  | Microsimulation: FPM, ASF (+now()) | 3.70 | 7.26 | 13.20 | | 0.88 | | 0.86 | | 0.86 | |
|  | Microsimulation: FPM, ASF (, now()) | 3.57 | 6.27 | 9.26 | 0.77 | | 0.56 | | 0.34 | |
|  | Microsimulation: FPM, RSF (+now()) | 3.69 | 7.19 | 12.69 | | 0.88 | | 0.83 | | 0.76 | |
|  | Microsimulation: FPM, RSF (, now()) | 3.57 | 6.27 | 9.14 | 0.78 | | 0.55 | | 0.31 | |
| RFC | Observed | 3.68 | 6.54 |  | | 0.84 | | 0.61 | |  | |
|  | Semi-Markov: SPM (Williams 2017) | 3.64 | 5.80 | 6.68 | | 0.77 | | 0.32 | | 0.03 | |
|  | Semi-Markov: FPM | 3.63 | 6.05 | 8.20 | | 0.77 | | 0.46 | | 0.21 | |
|  | Microsimulation: SPM, ASF (+now()) | 3.62 | 5.81 | 6.79 | | 0.76 | | 0.32 | | 0.05 | |
|  | Microsimulation: FPM, ASF (+now()) | 3.78 | 7.47 | 13.59 | | 0.91 | | 0.89 | | 0.89 | |
|  | Microsimulation: FPM, ASF (, now()) | 3.67 | 6.52 | 9.48 | 0.82 | | 0.58 | | 0.31 | |
|  | Microsimulation: FPM, RSF (+now()) | 3.78 | 7.40 | 13.10 | 0.91 | | 0.86 | | 0.78 | |
|  | Microsimulation: FPM, RSF (, now()) | 3.67 | 6.52 | 9.38 | | 0.82 | | 0.58 | | 0.29 | |
| RMST, restricted mean survival time; FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; SPM, standard parametric models; FPM, flexible parametric models; ASF, all-cause survival framework; RSF, relative survival framework. | | | | | | | | | | | |